Moderna Stock Doubles, Adding $26.4 Billion After Cancer Vaccine Meets Both Phase 3 Goals

thecryptobasic2026-08-19 13:18:36

Favorite

Moderna Stock Doubles, Adding $26.4 Billion After Cancer Vaccine Meets Both Phase 3 Goals

Moderna stock more than doubled at its premarket peak Wednesday after the company’s personalized mRNA cancer treatment, developed with Merck, succeeded in a pivotal Phase 3 melanoma trial. MRNA rose by approximately 105% from Tuesday’s $62.96 closing price, reaching an estimated peak near $129.07.

Visit Website

Disclaimer: This article is copyrighted by the original author and does not represent MyToken’s views and positions. If you have any questions regarding content or copyright, please contact us.(www.mytokencap.com)contact

About MyToken:https://www.mytokencap.com/aboutusArticle Link:https://www.mytokencap.com/news/593561.html

More exciting content is available on
X(https://x.com/MyTokencap)or join the community to learn more:MyToken-English Telegram Group
（https://t.me/mytokenGroup）

Previous:13F 新信号：AI 并未退潮，华尔街只是变得「挑剔」

Next:泡沫退潮后的加密VC：逃离者退场，深耕者加仓

XRP Exchange Reserves Decline as Upbit Holds 6.4 Billion XRP Near Early-Summer Highs

XRP reserves across three top crypto exchanges have declined by roughly 240 million XRP since late M...

thecryptobasic2026-08-19 14:53:48

Broadcom Loses $87 Billion as Google Gives Marvell Bigger AI Chip Role

Broadcom shares fell nearly 5% on Wednesday after Google expanded its custom-silicon partnership wit...

thecryptobasic2026-08-19 14:34:04

Nebius Loses $4.3 Billion in Market Value as Convertible Offering Fuels Dilution Fears

Nebius Group shares fell sharply Wednesday after the AI infrastructure company proposed another mult...

thecryptobasic2026-08-19 14:09:11